Targeting a Glioblastoma Cancer Stem Cell Population Defined by EGF Receptor Variant III

David R. Emlet\textsuperscript{1*}, Puja Gupta\textsuperscript{1*}, Marina Holgado-Madruga\textsuperscript{2*}, Catherine A. Del Vecchio\textsuperscript{3*}, Siddhartha S. Mitra\textsuperscript{4*}, Shuang-Yin Han\textsuperscript{5}, Gordon Li\textsuperscript{6}, Kristin C. Jensen\textsuperscript{7,8}, Hannes Vogel\textsuperscript{7}, Linda Wei Xu\textsuperscript{6}, Stephen S. Skirboll\textsuperscript{6,8}, and Albert J. Wong\textsuperscript{1}

\textsuperscript{1}Brain Tumor Research Laboratories, Program in Cancer Biology, Stanford University Medical Center, Stanford, CA 94305.

\textsuperscript{2}Department of Physiology and Pharmacology, IBSAL, School of Medicine, University of Salamanca, C/Alfonso X El Sabio s/n. 37007 Salamanca, Spain.

\textsuperscript{3}Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142

\textsuperscript{4}Institute of Stem Cell Biology and Regenerative Medicine, 265 Campus Drive, Stanford, CA 94305.

\textsuperscript{5}Department of Gastroenterology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, People’s Republic of China.

\textsuperscript{6}Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 943005.

\textsuperscript{7}Department of Pathology, Stanford University Medical Center, Stanford, CA, 94305.

\textsuperscript{8}Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94305.

Running title: Defining and Targeting GBM CSCs with EGFRvIII

Keywords: Glioblastoma, Cancer Stem Cells, EGF Receptor Variant III, EGFRvIII-CD133 bispecific antibody

\textsuperscript{*}These authors contributed equally to this manuscript
A.J.W. is supported by National Institutes of Health grants CA69495, CA124832, 1RC2CA148491, and research grants from the California Institute for Regenerative Medicine, National Brain Tumor Foundation and Lucille Packard Children’s Foundation

Corresponding author:

Albert J. Wong, M.D.

Program in Cancer Biology/Department of Neurosurgery

Stanford University Medical Center

1201 Welch Road, MSLS P105

Stanford, CA 94305-5327, USA

Tel: 650-736-4220

Email: ajwong@stanford.edu

Conflicts of interest: none

Word count: 4314

Number of figures and tables: 6 figures
Abstract:

The relationship between mutated proteins and the cancer stem cell population is unclear. Glioblastoma tumors frequently express EGFRvIII, an EGFR variant that arises via gene rearrangement and amplification. However, expression of EGFRvIII is restricted despite the prevalence of the alteration. Here we show that EGFRvIII is highly co-expressed with CD133 and that EGFRvIII+/CD133+ defines the population of cancer stem cells with the highest degree of self-renewal and tumor initiating ability. EGFRvIII+ cells are associated with other stem/progenitor markers while markers of differentiation are found in EGFRvIII− cells. EGFRvIII expression is lost in standard cell culture but its expression is maintained in tumor sphere culture, and cultured cells also retain the EGFRvIII+/CD133+ co-expression and self-renewal and tumor initiating abilities. Elimination of the EGFRvIII+/CD133+ population using a bispecific antibody reduced tumorigenicity of implanted tumor cells better than any reagent directed against a single epitope. This work demonstrates that a mutated oncogene can have CSC specific expression and be used to specifically target this population.
INTRODUCTION:

The cancer stem cell (CSC) hypothesis has been a useful concept for explaining several biologic properties of tumors, including the observation that stem-like cells are tumorigenic while most of a tumor consists of differentiated cells with low tumor forming ability (1). Whether this principle can be exploited to enhance therapy is not clear. The CSC population may not necessarily represent the original tumor initiating cell (2) and there is plasticity in the general tumor mass such that cells can reacquire a CSC-like phenotype. The repertoire of markers available for identification of CSC also complicates therapy. Stem cell markers and other cellular proteins have been shown to enrich for CSCs but these otherwise normal proteins lack tumor specificity and no marker has precisely selected for these cells (3-5).

Mutations or rearrangements in genes that potentially drive neoplasia can be identified in many cancers. In vitro work has shown that the resulting oncogenic proteins can contribute to CSC related pathways (6). It stands to reason that the products of such altered genes could be used to identify and potentially target CSCs. In practice this has been difficult to establish because driver mutations are present in cells throughout the mass and typically are not specific to any subpopulation. Thus, mutant proteins may not have any direct role in CSCs and perhaps only generally potentiate tumor growth (7). In addition, most altered proteins are intracellular.

While not all tumors follow a CSC model, glioblastoma (GBM) has been strongly associated with the presence of CSCs (3, 8). Amplification of the EGFR gene is common in this tumor, and 20-40% of GBMs express EGFRvIII, an altered form of the EGFR gene which arises via gene rearrangement and amplification (9). Some studies have seen EGFRvIII expression as high as 70% in GBM (10). In addition to GBM, EGFRvIII has been found in a high percentage of breast
importantly, it is rarely found in normal tissue (11) and this almost exclusive expression in tumors makes it an intriguing target for therapy (14). The presence of EGFRvIII correlates with a worse prognosis for both glioblastoma and anaplastic astrocytoma patients (15, 16). EGFRvIII expression is strongly associated with the “classical” molecular subtype of glioblastoma where it is found in conjunction with PTEN mutations but is mutually exclusive with P53 or IDH1 mutations (17). Other laboratories and ours have shown that a peptide vaccine targeting the EGFRvIII antigen can effectively reduce tumor progression in preclinical models (18). Human clinical trials have demonstrated improved overall survival and an EGFRvIII specific immune response in patients treated with the vaccine in several Phase II trials (14, 19).

Despite this improvement in patient survival, a paradoxical observation is that the typical expression pattern for EGFRvIII in positive tumors is either sporadic cells or focal areas of positive cells, unlike wildtype (wt) EGFR which is usually broadly seen across the same tumor (20, 21) despite prevalence of the gene rearrangement/amplification (22). Interestingly, gene amplification in GBM is a clonal event (23) where only one gene rearrangement is seen in EGFRvIII+ tumors (9, 24). These observations point to EGFRvIII being an early development in tumorigenesis. Thus, the restricted expression of EGFRvIII may reflect its association with the CSC population. CSCs show enhanced resistance to radiation therapy and increased DNA repair mechanisms (25) and interestingly, EGFRvIII+ cells are also highly resistant to ionizing radiation due to increased DNA repair mechanisms (26). On the other hand, EGFRvIII expression may only promote growth or have a less specific paracrine function via expression of cytokines (7). Because EGFRvIII is the result of an early genetic alteration and is a transmembrane receptor, it provides a unique opportunity to test if mutated oncogenes can indeed play a role in CSCs.
Materials and Methods:

Dissociation of primary human brain tumors and culture. Freshly resected human glioblastoma tumor samples were obtained from the Stanford University tissue and brain bank under IRB approved protocols. Dissociated tissue samples were cultured on non-adherent plates using defined media containing EGF, bFGF, and heparin. For neurospheres from non-neoplastic tissue, recombinant human LIF was also added. For experiments in which tumor spheres were induced to differentiate, cells were cultured in the same media without EGF and FGF plus the addition of either 5% Fetal Bovine Serum and 5% Horse Serum, or by a cocktail of CNTF, BDNF and retinoic acid.

Flow cytometry. Freshly dissociated cells were co-stained with a monoclonal anti-EGFRvIII antibody (G100) (13) or rabbit anti-EGFRvIII and CD133/1-APC and CD133/2-APC. Cells from the primary tumor itself were used for compensation using an anti-MHC I biotin antibody. Appropriate isotype controls were used to control for non-specific isotype background. Sorted cells were collected in tumor stem media and used for orthotopic intracranial transplantation or in vitro assays.

Limiting dilution and tumor sphere formation analysis. Limiting dilution analysis (LDA) was done as described previously. An extreme LDA algorithm was used to determine the frequency of renewing cells (27). To estimate the ability to form tumor spheres after ADCC, NK cells were separated from GBM cells using the MACS lineage depletion kit (Miltenyi Biotech). For the secondary sphere assay, spheres generated during the LDA were re-dissociated and plated 10 cells per well on a 96 well plate and the number of spheres counted after 8 weeks.
**Intracranial transplantation and tumor formation.** 6-8 week NOD-SCID mice were intracranially injected and monitored for 22-26 weeks or until neurological defects were observed. For experiments to test for an anti-tumor effect of the BsAb, human GBM tumor cells were mixed with either BsAb, human IgG1-Fc, di-EGFRvIII or di-CD133 at a final concentration of 0.01ug/100,000 cells prior to injection without pre-incubation.

**Immunohistochemistry (IHC) and immunofluorescence (IF).** IHC was performed according to standard protocols. For the anti-CD31 and anti-EGFRvIII double labeling, the MACH 2 double stain kit was employed using the Vulcan Fast Red chromagen to detect the anti-CD31 antibody. For staining of cultured tumor spheres, spheres were fixed with paraformaldehyde, permeabilized with Triton X-100, and subjected to a standard PBS-based immunofluorescence protocol. For immunofluorescence samples were visualized using a Leica SP2 confocal microscope with a 63x oil immersion objective.

**Creation, expression and purification of antibody constructs.** Anti-CD133 scFv was obtained by PCR amplification of the variable regions of the light and heavy chains from AC133.1 hybridoma (ATCC No. HB-12346). Assembly of the scFv was done by splicing using overlap extension PCR and the purified PCR product cloned into phagemid pAK100 (kind gift from Prof. Andreas Pluckthun). Anti-EGFRvIII scFv was artificially synthesized based on the published sequence available from Genbank (accession no.U76382). A pBudCE4:Her2:CD16 bispecific minibody vector was used as the base vector and was a kind gift from Dr. Louis Weiner. This construct has scFv against Her2/neu and CD16 in a bi-cistronic vector and the CH3 region has a "knob-into-hole" configuration to enhance heterologous dimer formation. We replaced the scFv’s for Her2/neu with the scFv of anti-EGFRvIII Ab and anti-CD16 scFv with
the scFv of anti-CD133. V5 and His6 tag sequences are present at the 3'-end of the anti-EGFRvIII binding arm, and Myc and His6 tag sequences are present at the 3'-end of the anti-CD133 binding arm. As controls, antibodies containing either two scFv chains against AC133 or EGFRvIII were also created. The constructs were stably transfected into HEK 293 cells. Antibodies were purified from prepared supernatant using a His-Trap column protocol (Amersham Biosciences).

**Plasma membrane preparation and ELISA for BsAb Analysis.** Plasma membrane protein was quantitated and adsorbed onto 96 well ELISA plates. Wells were blocked with human γ-globulin and incubated with different concentrations of antibody. The secondary antibody used to detect bound antibody was THE™ Anti-c-Myc-tag [HRP] mAb (Genscript). Plates were developed using the SureBlue TMB Microwell Substrate (KPL).

**Live cell immunoprecipitation.** Cell lines expressing EGFRvIII, CD133 or both were dissociated, blocked with human γ-globin and counted. Viable cells were incubated with various concentrations of antibodies. For a qualitative analysis of affinity, the cells were lysed and processed for immunoblot analysis with anti-CD133, anti-EGFRvIII or anti-V5 antibodies. For quantitative analysis of surface bound antibody, live cells were eluted with glycine stripping buffer. Eluted antibody was neutralized and adsorbed on 96 well plates and detected using HRP labeled anti-myc antibody.

**Competitive sandwich ELISA assay.** U87 cells lines expressing either or both epitopes (10⁴ cells to 10⁹ cells) were incubated with 400nM BsAb and then added to 96 well plates coated with the membrane fraction from U87 cells transfected with both EGFRvIII and CD133 (~10⁵ cells). The cells were then washed off and membrane fraction bound BsAb was quantitated.
NK cell purification and culture. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation. NK cells were purified using anti-CD56-coated microbeads, followed by two rounds of positive selection using autoMACS. CD3^+ cells were subsequently depleted using anti-CD3 coated magnetic beads.

Cytotoxicity assay. The antibodies were tested for their ability to induce antibody dependent cellular cytotoxicity (ADCC) using NK cells as the effectors against target cells. The aCella-Tox kit was used to quantitate ADCC (Cell Technology, Inc.). The protocol was carried out according to the manufacturers’ recommendation and luciferase activity was measured using a luminometer.

Cell lines and expression plasmids utilized. U87 cells expressing EGFRvIII (U87vIII) were a kind gift of Dr. Donald O’Rourke. U87-EGFRvIII/CD133 double expressing cells lines were generated by stable transfection of EGFRvIII and CD133. The CD133 clone was obtained from Plasmid Information Database (PlasmID) maintained by Dana-Farber/Harvard Cancer Center DNA Resource Core. The CD133 gene was PCR amplified and subcloned into the pCR3.1 vector. EGFRvIII was also subcloned into the pCR3.1 vector (28).

Statistical analysis. To validate the significance of the observed differences we analyzed variables using two-sided t tests or two-way ANOVA. Differences in survival estimates were calculated using the Log Rank test.
RESULTS:

EGFRvIII is found in primary human GBM CSCs.

CD133 has been widely used for the identification of GBM CSCs (3). While some studies have found it to be problematic (29-31), it still remains one of the most generally used markers and has now been used to identify CSCs from colon, lung, ovary and prostate tumors among many others. We reasoned that if EGFRvIII is found in CSCs, then it may show an association with CD133. We first analyzed 28 freshly resected GBM samples by flow cytometry to assess EGFRvIII and CD133 expression. Figure 1A shows representative flow cytometry plots from three tumors, two showing co-expression of EGFRvIII and CD133 (GBM10 & GBM13) and one EGFRvIII+/CD133+ tumor (GBM15). The gating strategy for these results is demonstrated in Figure S1. We found that 57% (16/28) of tumors were CD133+ (as well as two normal brain (NB) samples from adult resections of epileptic seizure foci), 71% (20/28) were EGFRvIII+, and 81% (13/16) of the CD133+ tumors also expressed EGFRvIII (Fig. 1B). Patient time-to-recurrence, survival, EGFRvIII/CD133 status, tumor location, and treatment data for available samples are shown in Table S1, and EGFRvIII/CD133 expression in all samples is shown in Table S2. We consistently observed a significant fold increase in the actual percentage of cells which express both proteins as compared to the co-expression expected through random co-incidence (Fig. 1C, p<0.001 for average of entire set), demonstrating that EGFRvIII is preferentially expressed with CD133 in a subset of tumor cells.

Tumor derived neurospheres, or tumor spheres are widely used as an in vitro model for studying CSCs, and EGFRvIII has been shown to be expressed in these cells (32, 33). We hypothesized that the EGFRvIII+ cells should show enhanced tumor sphere forming ability. Using limiting dilution analysis of the four sorted populations from six primary GBM samples, we observed that
EGFRvIII+/CD133+ and EGFRvIII+/CD133- cells had the highest frequency of GBM sphere initiating cells (1/64 and 1/127 respectively) as compared to EGFRvIII+/CD133+ (1/211), and EGFRvIII+/CD133- cells (1/1032) (Figure 1D). Re-dissociated tumor spheres from EGFRvIII+/CD133+ and EGFRvIII+/CD133- cells consistently showed the highest potential for sphere self-renewal compared to the EGFRvIII+/CD133+ populations (Figure 1E). Additionally, we observed in EGFRvIII+/CD133- tumors that selection for EGFRvIII+ resulted in a population capable of self-renewal whereas the EGFRvIII- population showed no self-renewal (4/4 tumors analyzed).

An essential property of CSCs is tumor forming ability in mice. CD133+ cells from primary GBM tumors show enrichment for tumor formation when implanted intracranially into NOD-SCID mice (3). Figure 1F shows representative tumors formed 4 weeks and 24 weeks after injection with EGFRvIII+/CD133+ versus EGFRvIII+/CD133+ primary GBM cells. Review of the histopathology of these tumors shows several classic features of glioblastoma including increased vascularity, pseudopalisades, increased mitoses, and varied cellular morphology, but there did not appear to be any consistent difference in tumor histology among the immunophenotypic groups. Also, it has been reported that glioblastoma CSCs exist in a perivascular niche (34) and can transdifferentiate (35, 36) into endothelial cells. Interestingly, when both primary human GBM samples and mouse xenografts from cultured human GBM tumor spheres were stained for EGFRvIII alone or EGFRvIII in combination with the endothelial marker CD31, they occasionally revealed the presence of EGFRvIII around and in vessels (Fig. S2). In primary human GBM samples, this staining pattern was observed in 23% of human GBM tumors analyzed (5/21), demonstrating another property that EGFRvIII+ cells have in common with CSCs. In agreement with previous reports (20, 21), overall EGFRvIII staining appeared to be either sporadic or focal with no strong association with the edges of necrotic areas.
Using six GBM samples, we found that 83% (15/18) of mice receiving EGFRvIII+/CD133+ cells, and 33% (4/12) of mice receiving EGFRvIII+/CD133− cells developed tumors, whereas only 28% (5/18) of mice receiving EGFRvIII−/CD133+ cells showed tumors (Fig. 1G). None of the mice (0/18) injected with EGFRvIII−/CD133− cells developed tumors even with doses as high as 100,000 cells. The survival probability of EGFRvIII+/CD133+ cell injected mice was also significantly decreased as compared to mice injected with the EGFRvIII+/CD133− or EGFRvIII−/CD133+ population (Fig. 1H).

**EGFRvIII+ tumor spheres recapitulate properties observed with primary tumor cells.**

EGFRvIII amplification and expression is rapidly lost when GBM tumors are grown under standard serum based culture conditions (37). However, because tumor spheres represent the CSC population in cell culture if EGFRvIII expression marks a CSC population, then its expression should be retained in spheres grown under stem cell culture conditions. EGFRvIII expression was found in all EGFRvIII+/CD133+ cultured tumor spheres (GBMsp) derived from EGFRvIII+/CD133+ primary GBMs when examined by immunoblot, RT-PCR, flow cytometry, and immunofluorescence (Fig. 2 A-C, Fig. 3 and 4). Expression was not detected in cultured spheres derived from normal tissue or primary GBM tumors that were EGFRvIII− by flow cytometry. These data demonstrate that EGFRvIII does not arise spontaneously during culture, and also suggest that it is the selection for CSC properties that preserves EGFRvIII expression in tumor spheres. EGFRvIII+ tumor sphere cells also co-express CD133 (Fig. 2C), maintain greater than expected co-expression of both receptors (Fig. 2D), and are the highest self-renewing population of cells (Fig. 2E), just as in the original tumors. Lastly, EGFRvIII+ cultured tumor spheres are also tumorigenic, as orthotopic transplantation of 10⁴ cells into NOD-SCID mice cortex formed high grade glioma tumors (Fig. 2F). This data extends the results of others.
showing EGFRvIII expression in spheres (38, 39) by suggesting that it is the EGFRvIII+ cells that are the key cells within GBM tumor spheres for self-renewal and tumorigenicity. Overall, the data from figures 1 and 2 support our hypothesis that EGFRvIII identifies a putative CSC population. The fact that the EGFRvIII+/CD133+ population showed the highest tumor formation and self-renewal capacity suggests that the use of these two markers further refines detection of the CSC population.

EGFRvIII association with stem cell markers.

Much like neural stem cells, during differentiation GBM CSCs lose expression of stem cell markers and express markers for neural and astrocytic lineages (40, 41). Immunoblot and RT-PCR analysis comparing undifferentiated vs. differentiated tumor sphere samples showed that loss of EGFRvIII expression upon differentiation correlates with the loss or reduction of expression of the stem/progenitor cell markers CD133 and SOX2. Conversely, differentiation resulted in the expression of the glial lineage marker GFAP (Fig. 3 A, B). To better understand on a cell-by-cell basis the effects of differentiation on EGFRvIII and other markers, we performed immunofluorescence microscopy. In cultured tumor spheres, EGFRvIII showed no co-expression with vimentin, and only very low co-expression with GFAP or TuJ1, but showed a ~ 4-17 fold greater co-expression with nestin and SSEA-1 (Fig. 4 and Table S3). GBM tumor sphere (GBMsp) cells were differentiated by culture in 10% serum, and similar to Figure 3 all sphere lines examined lost all EGFRvIII expression, as well as SSEA-1 expression, yet maintained GFAP, Vimentin and TuJ1 (Fig. 4 Differentiated). Of note, wtEGFR expression was maintained upon differentiation (data not shown). These findings strongly support the notion that EGFRvIII expression can define a subpopulation of stem/progenitor-like cells in GBM by showing that EGFRvIII is associated with markers of undifferentiated cells that is lost upon differentiation while markers of differentiation are maintained or gained.
Development of a bispecific EGFRvIII/CD133 antibody.

If EGFRvIII defines a CSC population, then depleting EGFRvIII+ and more specifically EGFRvIII+/CD133+ cells should prevent tumor formation. A bispecific antibody that recognizes EGFRvIII and CD133 would have the highest affinity towards a cell expressing both proteins but lower affinity towards cells expressing either antigen alone. Single chain variable fragments (scFv) against CD133 and EGFRvIII were cloned. The scFv against EGFRvIII has been previously described (42) and the scFv against CD133 was generated as described in the Methods. These scFv were combined to create the anti-EGFRvIII/CD133 chimera named BsAb (bi-specific antibody), and bi-valent constructs for EGFRvIII (di-EGFRvIII) and CD133 (di-CD133). Each construct contains a human IgG1-Fc domain for engaging natural killer (NK) cells (Fig. 5A). We confirmed that the BsAb has the highest binding for cells expressing both epitopes, whereas di-EGFRvIII and di-CD133 have high affinity for cells expressing only high levels of each protein respectively (Fig. 5B, S3A and B). EGFRvIII+/CD133+ cells bound BsAb at concentrations as low as 200 nM, whereas mixtures of cells expressing each antigen independently showed low affinity towards the BsAb even at 2000 nM (Fig. 5B). The BsAb does not cross-link cells independently expressing each protein as pools of U87-EGFRvIII and U87-CD133 cells do not bind (Fig. 5B and S3C). To be effective the BsAb must be able to identify a rare stem cell population amongst the more abundant differentiated cell population. Comparison of an EGFRvIII specific antibody to the BsAb by IHC demonstrates that the BsAb recognizes only a subset of cells recognized by the EGFRvIII antibody in GBM samples (Fig. S3D), and a competitive sandwich ELISA using EGFRvIII+/CD133+ cells showed that the BsAb bound to dual epitope expressing cells even in the presence of a vast excess of cells expressing individual proteins (Figure 5C). Furthermore, using four different neurosphere lines (3 tumor, 1 non-neoplastic) we found specific binding of the BsAb correlated with EGFRvIII+/CD133+...
expression (Figure 5D). These results demonstrate that the BsAb preferentially binds to individual cells co-expressing both proteins.

**The BsAb is cytotoxic to human GBM cells**

We established that di-EGFRvIII and BsAb exhibited significant NK cell induced toxicity towards U87-EGFRvIII/CD133 cells (Fig. S4A). Then, using a effector to target (E:T) ratio of 10:1, we found as little as 0.1ug/ml (8.3nM) of BsAb was sufficient to induce cytotoxicity in EGFRvIII+/CD133+ cells (Fig. S4B). Mirroring the binding results, the BsAb induced the greatest cytotoxicity in EGFRvIII+/CD133+ cells while the di-valent constructs worked best in cells expressing only the respective epitope (Figure S4C). Finally we tested freshly resected GBM tumor (GBM-8) or dissociated GBMsp to assay cytotoxicity towards cells from human patients. In GBM-8 and GBMsp lines that had high EGFRvIII+/CD133+ cells (GBMsp-4 and GBMsp-6), the BsAb induced higher cytotoxicity compared to GBMsp lines which expressed either CD133 (GBMsp-14, GBMsp-15) or EGFRvIII (GBMsp-17) alone (Figure 6A).

Importantly we also found low toxicity towards normal neural stem cells (NBsp-1, NBsp-2).

**The BsAb decreases self-renewal and tumorigenicity.**

Limiting dilution analysis of GBMsp cells pre and post cytotoxicity assay showed a significantly decreased renewal capability from BsAb treatment, while di-EGFRvIII was effective to a lesser degree, and a human IgG1-Fc fragment had no effect. No reagent significantly affected normal brain neurospheres (Figs. 6B, and S5). For tumor prevention analysis, the antibody constructs (all at 0.01ug/10^5 cells) were combined with GBM or GBMsp cells and injected into the cortex of NOD-SCID mice, which were sacrificed after 26 weeks and analyzed for tumor formation (Figure 6C and 6D). The BsAb severely inhibited tumor formation (26 total mice, 1/22 mice showed tumor formation) (p<0.001) as compared to Hu-IgG1-Fc which showed no reduction (12
injected, 8/8 analyzed showed tumors). Di-EGFRvIII and di-CD133 did not statistically significantly reduce tumor formation (Figure 6D). Furthermore, the survival probability of mice receiving the BsAb is significantly increased compared to the mono-specific antibody recipients, strongly suggesting that targeting of the EGFRvIII+/CD133+ CSC population effectively prevents GBM formation (Figure 6E).

DISCUSSION:

Several studies have shown that EGFRvIII is expressed in tumor spheres derived from GBM samples, but whether this was incidental or significant to CSC biology has not been investigated (38, 39). We have found that EGFRvIII is associated with markers used to identify stem cells or CSCs including CD133, nestin, SOX2, and SSEA-1, but shows little to no association with markers of differentiation including vimentin, Tuj-1, and GFAP. EGFRvIII expression, which is difficult to maintain under standard conditions, is preserved using tumor sphere conditions but the differentiation of tumor spheres results in the loss of EGFRvIII. Cell populations containing EGFRvIII have the highest degree of self-renewal and tumorigenicity. Collectively, our data suggest that the EGFRvIII oncogene can be used to define the CSC population.

Antibodies and small molecule inhibitors against wtEGFR also bind to EGFRvIII, but are less potent against this variant (43-45). Thus, if EGFRvIII+ cells represent the tumor initiating population there may be a CSC basis for why anti-EGFR therapy has not been effective against tumors expressing EGFRvIII (46). Interestingly, a peptide vaccine against EGFRvIII has demonstrated improved overall survival for GBM patients in Phase II clinical trials (19). Our data also provides an explanation for why therapy directed against a minority of cells can be effective in increasing survival: it is the targeting of CSCs and not the bulk of the tumor that can
indeed be therapeutically effective (19). The vaccine is administered after total resection and
radiation/chemotherapy and serves to inhibit tumor recurrence. The finding that the anti-
EGFRvIII and BsAb can effectively prevent intracranial tumor formation suggests that it can be
used in a similar manner where patients are treated immediately post-resection to prevent tumor
recurrence. Because these antibodies are passive immunotherapy it would have specificity
against the cells responsible for recurrence and complement the effects of the vaccine if used in
combination. Recent preliminary experiments show that the BsAb can be used to treat existing
intracranial tumors in mice indicating that this agent can penetrate the blood brain barrier.
Whether the BsAb studied here can ultimately be used in clinical trials awaits further preclinical
work to confirm that it can induce the regression of pre-existing tumors in animal models.

While CD133 has been widely used to isolate CSC in many solid tumors, its use has been
debated (29-31). Clearly this marker can enrich for CSCs, but our work and other studies show
that the true CSC may comprise only a fraction of the marker positive pool. We have found that
EGFRvIII+/CD133+ primary tumor cells are the most highly enriched population for self-renewal
and tumorigenicity, strongly suggesting that the addition of EGFRvIII expression to CD133
expression more accurately defines a CSC population in GBM. An important corollary of the
CSC hypothesis is that elimination of the cancer stem cell population is necessary and sufficient
to eliminate a tumor. We tested this notion by developing the BsAb to precisely recognize
EGFRvIII+/CD133+ cells. The specific lysis of the EGFRvIII+/CD133+ population significantly
reduces the implantation of primary glioblastoma tumors in mice and prolongs survival. Because
these mice were observed for 26 weeks, this data also suggest that the spontaneous acquisition of
tumor initiating properties by non-EGFRvIII+/CD133+ cells is likely to be very low. Thus, our
findings provide support for the hypothesis that elimination of cancer stem cells is sufficient to
eradicate a tumor in vivo.
A dual marker approach may prove more specific than the targeting of a single marker for several reasons. Nearly all studies isolating CSCs have relied on normal stem cell markers, such as CD133 (3) or CD15/SSEA-1 (4, 47, 48), which would present a potential toxicity problem if used as a target. This is especially relevant in the case of brain tumors since the brain has a finite pool of stem cells and limited capacity for regeneration. Many markers have been proposed to define glioblastoma CSCs (3-5) yet no single marker has definitively isolated these cells. The true CSC population may comprise only a fraction of any marker positive pool. The addition of another marker provides an independent selection that enhances the identification of the CSC. This work represents another step towards the goal of precisely identifying the CSC population, which is likely to require a series of studies building upon this and other findings.

The BsAb could be useful in treating other tumor types such as ovarian, prostate, colon and lung, where CD133 (49) and EGFRvIII expression (11, 13) has been reported. However, our bispecific approach demonstrates a proof of principle that could be extended to other cell surface protein and stem cell marker combinations. It is likely there are other oncogenic receptors that show CSC specific expression. Amplification of growth factor receptors is a common event in aggressive malignancies and has been implicated in the genesis of tumors through expansion of the CSC population. For example, the overexpression of HER2 in breast cancer has been linked to an increase in the CSC population (50). As more receptors and CSC markers are identified, this unique approach can be used to develop strategies to identify tumor initiating cancer stem cells in a wide variety of malignancies.


Acknowledgements: We thank Navpreet Bains, Supriya Sharma and Fanny Pang for assistance in cell count quantitation, and Beth Hoyte for review and assistance with figure preparation. We also thank the Stanford University tissue bank for acquisition of tissue, Dr. Karen Sachs for help with statistical analysis, Dr. Kalle Söderström for help in developing ADCC assays and NK cell isolation, and Prof. Andreas Pluckthun for his gift of pAK100 phagemid.

Author Contributions: D.R.E. performed differentiation and localization studies, participated in the analysis and interpretation of the data, and writing of the manuscript. P.G. cloned and
constructed the di-EGFRvIII and di-CD133 plasmids, and assisted the immunofluorescence.

M.H.M. assisted in the design and construct of the BsAb and writing of the manuscript. CDV performed differentiation studies and performed data analysis and manuscript preparation. S.S.M. performed flow cytometry, tumorigenicity, BsAb tumor studies, and participated in the data analysis and writing of the manuscript. S.-Y. H. cloned the scFv fragments, designed and constructed the BsAb plasmid. G.L. assisted with the tumorigenicity experiments. K.J. and H.V. provided glioblastoma specimens and pathology review. L.W.X. retrieved patient data. S.S. studied the co-expression of EGFRvIII and CD133 by flow cytometry. A.J.W. initiated the concepts and designed the study, analyzed the data, supervised the overall project and wrote the manuscript.
Figure Legends:

Figure 1. EGFRvIII expression and functional characteristics. Primary GBM and normal brain samples were dissociated and analyzed. A) Flow cytometry plots of EGFRvIII (x axis) and CD133 (y axis) surface expression in live dissociated GBM cells. Representative plots are shown from 28 samples analyzed. B) Percentage of EGFRvIII and CD133 expressing cells in all samples tested, including two normal brain samples (NB) from adult seizure focus resection of epileptic brain. C) Comparison of actual versus expected co-expression. D) An extreme limiting dilution analysis algorithm was used to determine the frequency of GBMsp forming (●) EGFRvIII+/CD133+ cells, (■) EGFRvIII+/CD133- cells, (▲) EGFRvIII-/CD133+ cells, and (X) EGFRvIII-/CD133- cells. E) Neurospheres from (D) above were re-dissociated without sorting to assay for self-renewal of (●) EGFRvIII+/CD133+ cells, (■) EGFRvIII+/CD133- cells, and (▲) EGFRvIII+/CD133- cells. Plotted is the mean ± SEM. F) Sorted primary GBM samples were intracranially injected into NOD-SCID mice. Shown is representative H&E staining of brains injected with 1000 EGFRvIII+/CD133+ or EGFRvIII-/CD133+ cells at 4 weeks and 24 weeks post injection. Scale bars = 500μm. G) Tumor incidence from injection of sorted cells into the brains of NOD-SCID mice. * = statistical significance (p<0.001). H) Kaplan-Meier survival probability estimates of mice injected with sorted cells. * = statistical significance (p<0.001). See also Figures S1 and 2, and Tables S1 and 2.

Figure 2. Expression of EGFRvIII in Cultured GBM Neurospheres (GBMsp). Tumor spheres derived from dissociated primary human GBMs were cultured in stem cell media prior to analysis. A) Immunoblot analysis of lysates from cultured GBMsp (GBMsp), normal brain spheres (NBsp) from epileptic patients, and control U87MG and U87-vIII for EGFRvIII expression and β- actin. B) RT-PCR for EGFRvIII transcription from total RNA of cultured
GBMsp and normal brain (NB) and U87MG and U87-vIII samples as controls. C) Flow cytometry analysis of co-expression of EGFRvIII (x axis) and CD133 (y axis) in dissociated GBMsp. The left panels of each sample show isotype control background (mouse IgG1/IgG2B for CD133 and rabbit IgG for EGFRvIII), and the right panels show signal for anti-CD133 and anti-EGFRvIII. D) Comparison of actual versus expected CD133/EGFRvIII co-expression in all cultured GBMsp samples tested. E) Secondary sphere initiating (sp-Ic) frequency of 6 tumor sphere lines from cells sorted into 4 populations (∗) EGFRvIII+/CD133+, (■) EGFRvIII+/CD133−, (▲) EGFRvIII+/CD133+, (∇) EGFRvIII+/CD133−. *= statistical significance (p<0.01), **= statistical significance (p<0.001). F) Cultured GBMsp cells were intracranially injected into NOD-SCID mice and assayed for tumor formation. Shown are micrographs of H & E staining of three sphere lines (Scale bar = 500 μm).

Figure 3. Effects of Differentiation on EGFRvIII and Marker Expression. GBMsp were grown either as a suspension culture or adherent culture in tumor stem media or differentiated by withdrawing EGF and FGF and exposing to two separate differentiating conditions; CNTF, BDNF and retinoic acid (CNTF, BDNF, RA) or 5%FBS + 5% donor horse serum (FBS, DHS). A) Immunoblot analysis with anti-EGFRvIII, anti-CD133, anti-GFAP, and anti β-Actin as control. Four separate cell lines were tested; representative blots of GBMsp-6 are shown. B) Whole cell RNA was utilized in RT-PCR analysis with primers specific for EGFRvIII, CD133, and SOX2 gene products. Each experiment was performed in two different GBM sphere lines. Representative gels of GBMsp-8 are shown.

Figure 4. EGFRvIII is not co-localized with markers of differentiation in cultured GBMsp. EGFRvIII+ neurospheres were maintained in stem cell media (Sphere) or dissociated and differentiated with media containing 10% serum (Differentiated). Cells were immunostained
with antibodies against EGFRvIII (vIII) and: A) Glial Fibrillary Acidic Protein (GFAP), B) Vimentin (VIM), C) β-III Tubulin (TUJ1), D) Nestin (NESTIN), and E) Stage Specific Embryonic Antigen 1(SSEA-1), and imaged by confocal microscopy. Each staining combination was performed on three separate GBM neurosphere lines with similar results. Images are from GBMsp-8 (0.16μm sections). Scales = 37.5μm in A-E (Sphere), and 75μm in all Differentiated micrographs. See also Table S3.

**Figure 5. Characterization of the anti-CD133/anti-EGFRvIII bi-specific antibody (BsAb).**

A) Schematic of the BsAb showing scFv chains of anti-CD133 and anti-EGFRvIII. Igκ = leader sequence from kappa chain of human IgG1, V_L = variable light chain, (G3S)4 = hinge peptide, V_H = variable heavy chain, CH2-CH3 = Fc domain from human IgG1, Myc, V5 and His = tags for purification and identification. Di-valent anti-CD133 (di-CD133) and anti-EGFRvIII (di-EGFRvIII) antibodies were also created. B) ELISA dose-response analysis of the BsAb (●), di-EGFRvIII (■), and di-CD133 (▲), reagents on U87 cells co-transfected with EGFRvIII and CD133, and analysis of the BsAb reagent on an equal mix of cells transfected with either EGFRvIII or CD133 (x). * = statistical significance (p < 0.001). C) Competitive sandwich ELISA to identify specificity of BsAb towards EGFRvIII+/CD133+ cells. BsAb was not pre-incubated (●) or pre-incubated with U87 cells expressing either (▲) CD133, (●) EGFRvIII, or both proteins expressed in the same cell (EGFRvIII/CD133) (■), or a pool of cells expressing CD133 or EGFRvIII (■) prior to incubation with membrane fractions from U87-EGFRvIII/CD133 cells (10^5 cells/well). D) Live cell immunoprecipitation and ELISA analysis of BsAb binding to GBM tumor spheres in cultures with variable EGFRvIII and CD133 expression. (●) GBMsp-13, (■) GBMsp-8, (▲) GBMsp-14, (x) NBsp-1. * = statistical significance (p<0.001). Data points are represented as mean ± SEM of three individual experiments. See also Figure S3.
**Figure 6. BsAb eliminates EGFRvIII+/CD133+ cells from culture, enhances cytotoxicity, impairs GBMsp tumorigenicity, and enhances survival.** A) BsAb Antibody-Dependent Cell Mediated Cytotoxicity (ADCC) on primary GBM cells (GBM-8), GBM tumor spheres (GBMsp), and normal neurospheres from epileptic patients (NBsp). All experiments were carried out in triplicate. Error bars represent ± SEM. *= statistical significance (p<0.001). B) Fold-change in the frequency of NBsp and GBMsp initiating cells pre and post-ADCC. Data represented as change in sphere renewing frequency, with and without the presence of BsAb (red) di-EGFRvIII (blue), di-CD133 (green) and human-IgG1-Fc (grey). C) Antibodies were mixed with unsorted cells (100,000 total) from EGFRvIII+/CD133+ tumors, injected into the brains of NOD-SCID mice, and assayed after 26 weeks. Coronal sections from mouse brain were stained with H&E. D) Percent tumor bearing mice from four human glioma samples (GBMsp-4, GBMsp-6, GBM8 and GBM12) co-injected with the various antibodies. Mice were analyzed after 26 weeks. E) Kaplan Meier survival probability shows the BsAb significantly enhances survival (p<0.0001) as compared to the mono-specific antibodies. See also Figures S4 and S5.
Figure 2

A

B

C

D

E

F

GBMsp-2

GBMsp-6

GBMsp-8
Figure 3

A

B

Downloaded from cancerres.aacrjournals.org on September 23, 2017. © 2013 American Association for Cancer Research.
Targeting a Glioblastoma Cancer Stem Cell Population Defined by EGF Receptor Variant III

David R Emlet, Puja Gupta, Marina Holgado-Madruga, et al.

Cancer Res  Published OnlineFirst December 23, 2013.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-1407

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/12/23/0008-5472.CAN-13-1407.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.